Drug
Talquetamab clinical trials
Also written JNJ-64407564 and Talvey.
- studies test it
- 30
- open now
- 20
- in phase 3
- 7
- first study started
- 2017
Keep track of what changes. Save the talquetamab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
29 studies that test it; most in 2025 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 16
- Phase 3
- 7
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 19
Janssen Research & Development, LLC (10) · PETHEMA Foundation (1) · Janssen Pharmaceutical K.K. (1) · Alliance for Clinical Trials in Oncology (1) · University of Arkansas (1) · Polish Myeloma Consortium (1) · Montefiore Medical Center (1) · First Affiliated Hospital of Chongqing Medical University (1)
Often tested with
Tested in the same studies.
Teclistamab (14) · Lenalidomide (3) · Pomalidomide (2) · Ramantamig (2) · Dexamethasone (2) · Immune Checkpoint Inhibitors (1) · Daratumumab (1) · Melphalan (1)
Studies
Open first, then newest update. How each study uses talquetamab is read from its arms, and is right about nine times in ten.
Testing it · 30
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingPhase 2/3Alliance for Clinical Trials in OncologyNCT07887984Written as Talquetamab
- Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaRecruitingPhase 2Naresh BummaNCT07657312Written as Talquetamab
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT05552222Written as Talquetamab
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 2Janssen Research & Development, LLCNCT04634552Written as Talquetamab
- A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsRecruitingPhase 2Janssen Research & Development, LLCNCT06500884Written as Talquetamab
- MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple MyelomaNot yet recruitingPhase 2University of ArkansasNCT07029776Written as teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance
- A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseNot yet recruitingPhase 3Polish Myeloma ConsortiumNCT07740486Written as Talquetamab
- TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Not yet recruitingPhase 1Montefiore Medical CenterNCT07720843Written as Talquetamab
- Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple MyelomaRecruitingPhase 2Stanford UniversityNCT06461988Written as Talquetamab
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingPhase 3University of LeedsNCT07649525Written as Talquetamab
- Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaRecruitingPhase 2SCRI Development Innovations, LLCNCT05972135Written as Talquetamab
- Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.RecruitingPhase 2European Myeloma Network B.V.NCT07107529Written as Talquetamab
- Mezigdomide and Talquetamab in Relapsed and Refractory Multiple MyelomaRecruitingPhase 1Massachusetts General HospitalNCT07032714Written as Talquetamab
- Talquetamab in Patients With Refractory Generalized Myasthenia GravisNot yet recruitingNot applicableFirst Affiliated Hospital of Chongqing Medical UniversityNCT07499323Written as Talquetamab
- Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Alfred Chung, MDNCT06348108Written as Talquetamab
- A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell TherapyRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06066346Written as Talquetamab
- Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)RecruitingPhase 2Carl Ola Landgren, MD, PhDNCT06100237Written as Talquetamab
- Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 1Medical College of WisconsinNCT07093554Written as Talquetamab
- GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingPhase 2University of Heidelberg Medical CenterNCT05695508Written as Talquetamab
- Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma PatientsRecruitingPhase 2North Estonia Medical CentreNCT06505369Written as Talquetamab
See all 30 studies that test talquetamab →
Given in every arm · 8 — talquetamab is usual care beside what is tested
- Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early RelapseRecruitingPhase 2Larysa SanchezNCT06827860Written as Talquetamab
- Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple MyelomaRecruitingPhase 1Christopher StrouseNCT07581704Written as Talquetamb
- Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)RecruitingPhase 2Noffar BarNCT06993675Written as Talquetamab
- A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT05050097Written as Talquetamab
- A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2Janssen Research & Development, LLCNCT06577025Written as Talquetamab
- A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT04108195Written as Talquetamab
- Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2Nantes University HospitalNCT06353022Written as Talquetamab
- An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple MyelomaCompletedPhase 2CelgeneNCT03601078Written as Talquetamab
Codes
What other systems call talquetamab · ClinicalTrials.gg INT002094
- MeSH (NLM) C000730985talquetamabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 4W3KFI3TN3TALQUETAMABConfirmed FDA, NLM, Wikidata
- Wikidata Q116777032talquetamabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171840TalquetamabOne source FDA
- DrugBank DB16678One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730985 | talquetamab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 4W3KFI3TN3 | TALQUETAMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q116777032 | talquetamab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171840 | Talquetamab | One source FDA |
| DrugBank | DB16678 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.